Intelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest Update

Intelligent Bio Solutions Inc. (NASDAQ:INBS) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 91,000 shares, a growth of 107.3% from the February 29th total of 43,900 shares. Based on an average trading volume of 3,150,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 3.2% of the shares of the stock are sold short.

Institutional Investors Weigh In On Intelligent Bio Solutions

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. Sabby Management LLC purchased a new stake in Intelligent Bio Solutions Inc. (NASDAQ:INBS) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 126,650 shares of the company’s stock, valued at approximately $367,000. Intelligent Bio Solutions makes up 0.3% of Sabby Management LLC’s investment portfolio, making the stock its 26th largest holding. Sabby Management LLC owned approximately 8.52% of Intelligent Bio Solutions as of its most recent filing with the Securities & Exchange Commission. 32.97% of the stock is currently owned by hedge funds and other institutional investors.

Intelligent Bio Solutions Price Performance

NASDAQ:INBS traded down $0.23 during trading hours on Thursday, reaching $4.22. 44,802 shares of the company were exchanged, compared to its average volume of 3,351,177. The stock’s 50-day moving average is $4.24 and its 200-day moving average is $5.25. Intelligent Bio Solutions has a twelve month low of $2.28 and a twelve month high of $49.20. The firm has a market cap of $11.98 million, a PE ratio of -0.04 and a beta of 4.88. The company has a current ratio of 0.57, a quick ratio of 0.39 and a debt-to-equity ratio of 0.07.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings data on Friday, February 9th. The company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.24) by $1.17. The company had revenue of $0.76 million for the quarter. Intelligent Bio Solutions had a negative return on equity of 266.16% and a negative net margin of 544.63%. On average, sell-side analysts anticipate that Intelligent Bio Solutions will post -3.67 earnings per share for the current fiscal year.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.